芬太尼透皮贴剂在中度癌痛治疗中的临床观察  

Clinical Observation of Fentanyl Transdermal Patch in Treatment of Moderate Cancer Pain

作　　者：王昆[1] 宋伟[1] 佟仲生[1] 穆怀焕[1] 赵宏伟[1] 魏青[1] 赵秋生[1] 李淑芬[1] 唐继强[1] 

机构地区：[1]天津医科大学附属肿瘤医院除痛科,天津市300060

出　　处：《中国肿瘤临床》2006年第10期577-579,共3页Chinese Journal of Clinical Oncology

摘　　要：目的:观察芬太尼(多瑞吉)透皮贴剂在中度癌痛的治疗效果,探讨该贴剂使用的最佳时机。方法:选择98例成年癌痛患者,疼痛视觉模拟评分(VAS)为4～6分。芬太尼透皮贴剂从2.5mg剂型开始,每隔3天更换一次,用药时间为15天。治疗过程中观察患者的疼痛评分和药物的不良反应。结果:治疗前后的VAS比较有显著性差异(P<0.01);治疗过程中常见的不良反应为便秘、恶心、呕吐、头晕和嗜睡。结论:芬太尼透皮贴剂能安全用于中度癌痛患者的治疗,推荐使用时机为一、二阶梯镇痛药物常规剂量效果不满意且VAS评分为4～6分的癌痛患者。Objective： To investigate the effects of fentanyl-TTS （transdermal fentanyl, Durogesic） on the treatment of moderate cancer pain and the indication of administration for these patients. Methods： 98 adult patients with cancer pain were selected. The pain assessment score of visual analogue scale（VAS） was between 4 to 6. Fentanyl-TTS was administered from the dosage of 2.5mg. Alternation of Fentanyl-TTS was three days and the duration of treatment was 15 days. The score of VAS, side-effect of Fentanyl-TTS were observed during the procedure. Results： VAS before research was significantly higher than that after treatment of fentanyl-TTS （P〈0.01）. Constipation, nausea, vomiting, dizzy and drowsiness were common symptoms of side-effects. Conclusion： Moderate cancer pain could be well treated with fentanyl-TFS with a favourable safety profile. The indications was the patients whom the VAS was between 4 to 6 and cancer pain was bad treated with 1st and 2nd ladder analgesics.

关 键 词：疼痛 肿瘤 芬太尼透皮贴剂 镇痛 

分 类 号：R730.5[医药卫生—肿瘤]